Hillstream Bio Pharma Inc. HILS
We take great care to ensure that the data presented and summarized in this overview for Hillstream BioPharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in HILS
Top Purchases
Top Sells
About HILS
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Insider Transactions at HILS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 13
2024
|
Sireesh Appajosyula Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+31.73%
|
$10,000
$2.02 P/Share
|
|
Oct 08
2024
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+6.24%
|
$5,000
$2.09 P/Share
|
|
Oct 08
2024
|
Sireesh Appajosyula Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+23.4%
|
$5,000
$1.93 P/Share
|
|
Dec 15
2023
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
29,000
+15.63%
|
$0
$0.5 P/Share
|
|
Nov 30
2023
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+7.27%
|
$10,000
$1.0 P/Share
|
|
Jul 14
2022
|
Sireesh Appajosyula Chief Operating Officer |
BUY
Bona fide gift
|
Indirect |
7,576
+50.0%
|
-
|
|
Jul 14
2022
|
Sireesh Appajosyula Chief Operating Officer |
SELL
Bona fide gift
|
Indirect |
75,757
-100.0%
|
-
|
|
Jun 17
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.02%
|
$0
$0.78 P/Share
|
|
Jun 06
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.01%
|
$0
$0.68 P/Share
|
|
Jun 01
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
1
|
$0
$0.94 P/Share
|
|
May 25
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.02%
|
$0
$0.78 P/Share
|
|
May 20
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.02%
|
$0
$0.92 P/Share
|
|
May 19
2022
|
Randy Milby CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.02%
|
$0
$0.91 P/Share
|
|
Apr 18
2022
|
Randy Milby CEO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
240,526
+1.58%
|
$0
$0.22 P/Share
|
|
Jan 14
2022
|
Randy Milby CEO |
BUY
Conversion of derivative security
|
Direct |
921,288
+0.94%
|
$2,763,864
$3.2 P/Share
|
|
Jan 14
2022
|
Leonard L Mazur Director |
BUY
Open market or private purchase
|
Direct |
25,000
+16.81%
|
$100,000
$4.0 P/Share
|
|
Jan 14
2022
|
Leonard L Mazur Director |
BUY
Conversion of derivative security
|
Direct |
98,733
+50.0%
|
$296,199
$3.2 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 51.5K shares |
|---|